← Oncology Approval Tracker

FDA DECISION ·

Udenyca autoinjector

pegfilgrastim-cbqv · Coherus BioSciences

FDA approvalNew formulationChemotherapy-associated neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

A 6 mg single-dose prefilled autoinjector presentation to reduce infection risk associated with febrile neutropenia in eligible patients with nonmyeloid cancers receiving myelosuppressive therapy.

LAMPGEN ANALYSIS

Why it matters

The FDA approved another way to administer the existing pegfilgrastim biosimilar.

What research teams should watch

Track the delivery presentation in the medication record and verify patient training and timing after chemotherapy.

PRIMARY RECORDS

Sources